Upcoming Medical Policies
BlueCross BlueShield of Tennessee

Each medical policy listed below will become effective on the date indicated, and will be included in the Medical Policy Manual for BlueCross BlueShield of Tennessee on that effective date.

Medical policies are developed using an evidence-based evaluation process.  The medical evidence used in this process comes from several sources, including independent medical technology review organizations, the peer reviewed medical literature, and opinions from appropriate network specialists. All Medical Policies are reviewed by a panel of internal and external physicians before being adopted by the company.

Topics due to be included in the Medical Policy Manual on 5/10/2014

Topics due to be included in the Medical Policy Manual on 6/14/2014

Topics due to be included in the Medical Policy Manual on 6/18/2014

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Topics due to be included in the Medical Policy Manual on 5/10/2014:

Alemtuzumab

Certolizumab Pegol

Genetic Panel Assay for Psychiatric Disorders

Genetic Testing for Macular Degeneration

Topics due to be included in the Medical Policy Manual on 6/14/2014:

Analysis of MGMT (O6-methylguanine-DNA methyltransferase) Promoter Methylation

Cranial Electrotherapy Stimulation and Transcranial Magnetic Stimulation

Genetic Testing for Epilepsy

Kinesio Taping

Non-invasive Prenatal Testing Using Cell-free Fetal DNA (cffDNA)

Orthoptic Training for the Treatment of Vision or Learning Disabilities

Treatment of Congenital Port Wine Stains and Hemangiomas

Vincristine Sulfate Liposome injection

Topics due to be included in the Medical Policy Manual on 6/18/2014:

Temozolomide


Last Review Date: 4/17/2014